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Association of the DSS1 c.143G4A Polymorphism
with Skin Squamous Cell Carcinoma
Mario Venza1,7, Teresa Catalano2,7, Maria Visalli2, Isabella Venza3, Maria Lentini4, Maria Cristina Curia5,6,
Renato Mariani-Costantini5,6 and Diana Teti2
DSS1 and p53 are required for homologous recombination, but, although p53 inactivation has a key function in
skin tumorigenesis, there is no clear evidence supporting a function of DSS1. We screened the entire DSS1
coding sequence and p53 exons 5–8 in a series of 60 cases of skin squamous cell carcinoma (SCC). Mutational
analysis of p53 revealed tumor-associated mutations in 28 (46.7%) of the cases. No tumor-associated DSS1
mutations were detected; however, the germline DSS1 c.143G4A synonymous polymorphism had a significantly
higher frequency in patients with SCC (16.67%) versus healthy subjects (5%). DSS1 expression was evaluated
by quantitative real-time RT-PCR and immunohistochemistry. With respect to c.143G4G genotype, SCCs and
adjacent normal tissues carrying the c.143G4A polymorphism showed significantly lower DSS1 RNA and
protein levels and a prevalent cytoplasmic rather than nuclear localization of DSS1 protein. The assay for mRNA
stability revealed that the c.143G4A polymorphism affects DSS1 expression efficiency, but not mRNA decay.
We clearly showed that the c.143G4A variant is associated with reduced DSS1 expression at both the RNA
and protein levels and with altered traffic of the DSS1 protein from the cytoplasm to the nucleus. These
alterations could impair DSS1 function in DNA repair and may be implicated in skin cancer.
Journal of Investigative Dermatology (2010) 130, 1719–1725; doi:10.1038/jid.2010.21; published online 11 March 2010
INTRODUCTION
Squamous cell carcinoma (SCC) of the skin is the second
most frequent type of nonmelanoma skin cancer (Petter and
Haustein, 1998; Popp et al., 2000; Dooley et al., 2003). SCC
risk is linked to exposure to various carcinogens (De Hertog
et al., 2001; Bolshakov et al., 2003; Boukamp, 2005), cumula-
tive lifetime sun and UV radiation exposure, geographic
location, atmospheric ozone depletion (Bolshakov et al.,
2003), familial and personal history of skin cancer (Preston
and Stern, 1992), chronic inflammatory skin lesions, viral
infections, immunosuppressive treatments (Dooley et al.,
2003), and genetic factors (Brash et al., 1996; Fusenig and
Boukamp, 1998; Kubo et al., 2002; Popp et al., 2002; Hayashi
et al., 2003; Tsai and Tsao, 2004; Backvall et al., 2005;
Hussein, 2005; Boukamp, 2005). Individual susceptibility is
generally related to alterations in double-strand breaks (DSBs)
and DNA repair mechanisms (Gatz and Wiesmu¨ller, 2006;
Scott and Pandita, 2006). Homologous recombination (HR), an
error-free pathway of DSB repair in mammalian cells, leads to
a decrease in cancer cells carrying mutations in some genes
involved in HR (Reliene et al., 2007). Among these are
the well-known tumor-suppressor genes p53 and DSS1 (also
known as SHFM1, Shfdg1, and SEM1) (Crackower et al., 1996).
Mutations in p53, which cause genomic instability (Backvall
et al., 2005), are common in SCCs and precursor lesions
(Brash et al., 1996; Backvall et al., 2005) and are considered
early events (Kraemer and Di Giovanna, 2002; Backvall
et al., 2005; de Gruijl and Rebel, 2008).
DSS1 may work as a transducer of DNA-damage signals
(Kojic et al., 2003) and is required for the tumor-suppressor
activity of the breast cancer susceptibility gene BRCA2
(Marston et al., 1999; Gudmundsdottir et al., 2004; Kojic
and Holloman, 2004; Kojic et al., 2005; Li et al., 2006).
DSS1 is involved in the formation of nuclear foci that are
sites of DSB repair, and is probably required for the asso-
ciation of the BRCA2/RAD51 complex with sites of DNA
damage. Silencing of DSS1 results in chromosomal instability
(Gudmundsdottir et al., 2004), and loss of DSS1 protein
could compromise the BRCA2/DNA interaction required for
RAD51 oligomerization (Gudmundsdottir et al., 2004). DSS1
also has a relevant function in differentiation (Crackower
et al., 1996; Ja¨ntti et al., 1999), proliferation (Marston et al.,
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1999), and regulation of the 26S proteasome (Josse´ et al.,
2006; Wei et al., 2008). In mice, during embryonic
development, Dss1 expression is restricted to regions of
rapid cell growth (Crackower et al., 1996). Notably Dss1
expression is upregulated in murine UV-treated SCCs
(Rundhaug et al., 2005) and in murine 12-O-tetradecanoyl-
phorbol-13-acetate-treated keratinocyte progenitor cells and
hyperplastic skin lesions (Wei et al., 2003). These data led to
the hypothesis that Dss1 may be implicated in mouse skin
tumorigenesis (Wei et al., 2003).
To investigate the function of DSS1 in skin cancer, we
analyzed the DSS1 and p53 coding sequences in tumor and
normal samples of formalin-fixed, paraffin-embedded (FFPE)
skin from 60 cases of SCC from southern Italy.
RESULTS
The results of DSS1 analysis in 60 SCC cases and 200 control
blood samples are summarized in Table 1. The synonymous
c.143G4A variant at codon 5 in exon 1 was detected in
normal and tumor DNA in 10/60 SCC cases (16.67%) and
in 10/200 (5%) controls (P¼ 0.01). These findings support
the hypothesis that the DSS1 c.143G4A polymorphism is
inherited through the germline. No other DSS1 variant was
detected. None of 27 cell lines from non-skin cancers carried
the DSS1 c.143G4A polymorphism.
With regard to lifestyle, 29 of the 60 patients (48.3%) were
former or current cigarette smokers, 18 (30%) reported
alcohol consumption, 12 (20%) acknowledged both habits,
8 (13.3%) reported occupational and/or environmental UV
exposure, 3 (5%) both tobacco and UV exposure, and 4
(6.6%) both alcohol and UV exposure. The sun-exposed
areas of the head (scalp; forehead; supercilia; temporal,
zygomatic, and aural regions; cheeks; nose; lips) were the
most frequent tumor sites (91.8%), and the upper and lower
limbs accounted for 6.1 and 2.1% of the cases, respectively.
The histologically distinct SCC subtypes in the series included
acantholytic (30.5%), not otherwise specified (27.6%), clear
cell (12.5%), desmoplastic (8.4%), spindle cell (6.6%), and
other variants (bowenoid, lymphoepithelioma-like, basaloid,
keratoacanthoma-like, and verrucous, 14.4%). SCC cells were
graded as well, moderately, and poorly differentiated in 5/60
(8.3%), 45/60 (75%), and 10/60 (16.7%) cases, respectively.
With regard to p53 mutational analysis, 41 tumor-
associated p53 mutations were detected in 28/60 SCC cases
(46.7%). Of 39 nucleotide substitutions, 27 (69.23%) were
transitions and 12 (30.77%) transversions; 2 other mutations
were deletions (Table 2). Most of the detected mutations were
in exons 5 (17/41, 41.46%) and 6 (12/41, 29.27%), and the
remaining mutations were in exons 7 (5/41, 12.20%) and 8
(7/41, 17.07%). Seven cases presented two somatic mutations
in distinct codons: in two cases (nos. 7 and 29), the C4T
transition at codon 283 recurred in association with the
synonymous A4G variant at codon 213; two other cases
(nos. 24 and 33) exhibited C4T transitions at codons 152
and 177; one case (no. 11) had a C4T transition at codon
151 in association with a T4A transversion at codon 251;
and another (no. 10) carried both a G4T transversion at
codon 213 and a 13 bp deletion (CCGCCCGGCACCC) at
codons 152–156 (see Supplementary Table S2 online). Two
cases (nos. 19 and 32) reported three mutations: two CC4TT
and C4T transitions at codons 152 and 177, respectively,
and a T4A transversion at codon 205. The AC4TT double
substitution at codon 281 found in case 9—to our knowledge
previously unreported in the International Agency for
Research on Cancer TP53 mutations database, R13 version,
updated November 2008 (http://www-p53.iarc.fr)—was as-
sociated with a C4T transition at the first base of codon 282.
Seven cases with tumor-associated p53 mutations also
harbored the DSS1 c.143G4A variant.
We next correlated germline DSS1 c.143G4A genotype
status and tumor-associated p53 mutational status with
individual and familial history of skin cancer, reported
exposures to carcinogens, and histological tumor character-
istics. A personal history of multiple cutaneous cancers was
documented in all patients carrying somatic p53 mutations
associated with the germline DSS1 c.143G4A genotype,
and a family history of skin SCC was reported in two of
these cases. Carcinogen exposure was reported in all but
one of the patients with the DSS1 c.143G4A genotype.
Seven of the 10 cases with the DSS1 c.143G4A genotype
and somatic p53 mutations (70%) carried heterogeneous p53
base substitutions (C4A, A4T, T4A, A4G). The UV signature
C4T was not detected. With regard to histological charac-
teristics, four of the seven cases with tumor-associated p53
mutation andDSS1 c.143G4A carrier status were acantholytic,
two were not otherwise specified, and one was diagnosed
with clear cell carcinoma. Only in this last case were cells
poorly differentiated; the others were moderately differen-
tiated. To investigate DSS1 expression, we performed mRNA
quantification by quantitative real-time RT-PCR (QRT-PCR)
in matched tumor and normal skin from the 10 cases in
c.143G4A carriers versus the 50 cases in c.143G4G
Table 1. DSS1 c.143 polymorphism status in 60 skin
squamous cell carcinoma cases and in 200 healthy
controls
Cases (n=60) No. (%) Controls (n=200) No. (%) P-value1
c.143G4G 51 (83.33) c.143G4G 190 (95) 0.01
c.143G4A 10 (16.67) c.143G4A 10 (5) 0.01
1As calculated by ANOVA test.
Table 2. Summary of p53 mutations in 60 skin
squamous cell carcinoma cases
p53 mutation types No. (%)
Substitutions 39 95.12
Transitions 27 69.23
Transversions 12 30.77
Deletions 2 4.88
Insertions — —
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carriers. As shown in Figure 1a, a slight upregulation of DSS1
expression in the SCC area relative to matched normal skin
was observed, but, as shown in Figure 1b, the DSS1 mRNA
levels were lower in c.143G4A relative to c.143G4G
carriers for both normal skin and SCC (Po0.01). To explore
whether the polymorphism could affect the DSS1 mRNA
folding structure, we used the GeneBee Services prediction
method. This showed only a slight energy reduction in the
secondary structure of the mRNA with the G4A substitution
(Figure 2). Next, to test whether the DSS1 c.143G4A
polymorphism affected mRNA transcription and/or stability,
we compared the expression levels and decay rates of the
RNAs transcribed from the DSS1 c.143G and c.143A variants
in 293 EBNA cells transfected with the two pcDNA3.1
DSS1 constructs. Each construct carried DSS1 c.143G or
DSS1 c.143A and the neomycin gene, used to normalize
the transfection experiments. Total RNA was isolated from
transfected cells before and after treatment with actinomycin
D. After DNaseI treatment, QRT-PCR was performed for
the DSS1, neomycin, and b-actin genes. Analysis of two
independent transfection experiments showed that DSS1
c.143G produced a significantly higher quantity of mRNA
compared with DSS1 c.143A (Po0.01). The relative stability
of DSS1 c.143G variant was 0.29 Neo, whereas that of DSS1
c.143A was 0.31 Neo, indicating comparable mRNA tran-
script decay rates (Figure 3). A similar trend was found using
semiquantitative RT-PCR (data not shown).
Given that only nuclear DSS1 takes part in DSB repair,
we verified DSS1 localization through immunohistochemical
studies. As shown in Figure 4 (panels a and b), these inves-
tigations revealed clear DSS1 nuclear localization in most
tumor and normal cells of the cases with the DSS1 c.143G4G
genotype. In contrast, SCC and normal skin cells from
the cases with the c.143G4A genotype showed weaker
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Figure 1. Mean DSS1 RNA expression in skin squamous cell carcinoma and
normal skin. QRT-PCR was performed on total RNA from 60 skin squamous
cell carcinoma samples and 21 adjacent normal skin samples. Mean DSS1
expression values in skin squamous cell carcinoma (skin SCC) versus normal
skin from all cases (a) and from cases with DSS1 c.143G4A genotype versus
cases with c.143G4G genotype (b) are shown. Values represent the mean±SEM
from four independent determinations performed in triplicate. b-Actin was
used as a reference gene. **Po0.01 as calculated by ANOVA test.
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Figure 2. DSS1 mRNA folding structures. DSS1 c.143G4G and G4A
mRNA sequences were used for secondary folding structure model building
using the GeneBee Molecular Biology Server. Model structures for the
DSS1 mRNA of the G4G and G4A variants are shown on the left
and right, respectively. Arrows show the site of the polymorphism.
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Figure 3. The c.143G4A synonymous mutation in DSS1 leads to reduced
mRNA expression. QRT-PCR analysis of the c.143G4A and c.143G4G
variants, before and after actinomycin D treatment. b-Actin was used
as an internal control of gene expression. Relative RNA stabilities of
the DSS1 c.143G4A and c.143G4G variants were obtained by three
independent transfection experiments. The RNA level of each DSS1 variant
was normalized with neomycin (Neo), and the relative ratio before and
after actinomycin D is shown. **Po0.01 as calculated by ANOVA test.
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DSS1 expression, with prevalently cytoplasmic distribution
(Figure 4, panels c and d).
DISCUSSION
The data reported in this study are consistent with an
involvement of the DSS1 c. 143G4A polymorphism in skin
SCC. This variant exhibited a significantly higher frequency in
patients with SCC relative to healthy controls and was not
detected in any of the non-skin cancer cell lines studied,
suggesting a specific association with cutaneous SCC.
Previous reports showing that the involvement of DSS1
c.143G4A in breast cancer is unlikely (Syrja¨koski et al.,
2006; Tischkowitz et al., 2007) further support the hypothesis
that this polymorphism could be specifically implicated in
skin SCC. Synonymous mutations may not be selectively
neutral (Chamary and Hurst, 2005) because they may affect
the coding sequence and alter mRNA transcription, mRNA
folding stability, and rate of protein synthesis (Akashi, 2001;
Duan et al., 2003). Our results suggest that this could be the
case for DSS1 c.143G4A, because reduced DSS1 mRNA
and protein levels were observed in SCC and normal cells
from DSS1 c.143G4A carriers. Definitive evidence that
the c.143G4A allele is associated with decreased mRNA
transcription was provided by in vitro mRNA stability assays.
These showed that significantly reduced levels of DSS1
transcript were produced in c.143G4A versus c.143G4G
transfected cells, whereas the relative stability of the
mRNAs was not affected. The role of the DSS1 c.143G4A
variant in reducing mRNA expression may account for the
apparent discrepancy between our data and those obtained
by Rundhaug et al. (2005) in a murine skin carcinogenesis
model. In fact, we found decreased DSS1 expression in both
SCC and matched normal skin from c.143G4A carriers,
whereas a slight DSS1 mRNA increase was observed when
the SCC samples were compared with normal skin, indepen-
dent of polymorphism status. Measures of mRNA abundance
seem to be informative predictors of codon usage bias, and
levels of gene expression and codon usage have been well
correlated (Akashi, 2001). Reduced RNA transcription in
SCC cells carrying AAA instead of AAG at DSS1 codon 143
can be explained by codon usage bias. Moreover, DSS1
c.143G4A could affect translational efficiency because a
recent increase in mutational tendencies from GC to AT and a
weak selection influencing the fate of synonymous mutations
have been reported in evolutionary studies (Comeron, 2006).
The QRT-PCR and immunohistochemistry results of our study
show that DSS1 c.143G4A carrier status was associated with
reduced DSS1 expression at the RNA and protein levels and
with loss of nuclear localization, required for DSS1 function
in HR (Marston et al., 1999; Gudmundsdottir et al., 2004).
Alterations in DSS1 intracellular traffic could result in lack of
activation of DSB repair by HR in response to DNA damage.
Because DSS1 has no obvious nuclear localization signal,
it might be transported and anchored in the nucleus by
interaction with another protein, conceivably BRCA2
(Marston et al., 1999). Our observations suggest that the
low protein levels associated with the presence of the
c.143G4A variant could prevent interactions between
DSS1 and carriers, such as BRCA2, that could mediate
nuclear transport. This hypothesis is supported by studies of
the subcellular localization of wt DSS1 in pre-neoplastic
epidermal cells (Wei et al., 2003). Epidermal cells showing a
nuclear pattern of DSS1 expression presented a normal
morphology, whereas cells that expressed the protein in both
nuclear and cytoplasmic compartments presented a different
morphology, correlated to alterations in growth or differ-
entiation (Wei et al., 2003). Therefore, in c.143G4A
genotype carriers, the low levels of DSS1 gene and protein
expression and the altered DSS1 intracellular traffic could
predispose to SCC, particularly when combined to environ-
mental exposure to carcinogens. Carriers of the G4A variant
might be less resistant to environmental damage and could
be at higher SCC risk than homozygous c.143G carriers. These
results could support the hypothesis that DSS1 is a putative skin
cancer susceptibility gene (Syrja¨koski et al., 2006).
With regard to p53, we detected a double missense
mutation GAC4GTT at codon 281, followed by a C4T
substitution at codon 282, which, to our knowledge, is
previously unreported. The patient carrying this double
mutation had been exposed to UVR, alcohol, and cigarette
smoke. In addition, 11 mutations, never reported in skin SCC,
but described in other cancers, were detected in our series.
Two of these mutations, C4A at codon 127 and T4A at
codon 238, were found in DSS1 c.143G4A carriers.
Interestingly, a high percentage of the p53 mutated cases
(70%) carried the DSS1 c.143G4A variant, which suggests
that the DSS1 G4A polymorphism could predispose to
somatic p53 mutations. All patients exhibiting both the
DSS1 c.143G4A genotype and p53 somatic mutations had
Figure 4. Subcellular localization of DSS1 in skin squamous cell carcinoma
and normal skin of DSS1 c.143G4G and c.143G4A carriers. Tumor and
adjacent normal skin were immunostained with DSS1 antibody to determine
expression and localization of the DSS1 protein. Panels a and b, respectively,
show nuclear DSS1 expression in matched nonneoplastic skin and skin
squamous cell carcinoma samples of DSS1 c.143G4G genotype carriers.
Immunostaining in the nuclei is indicated by arrows (H&E counterstain, scale
bars¼ 50 and 500 mm, respectively). Panels c and d, respectively, show
cytoplasmic DSS1 protein immunostaining in matched nonneoplastic skin
and squamous cell carcinoma samples of DSS1 c.143G4A carriers (H&E
counterstain, scale bars¼ 50 and 500 mm, respectively).
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a personal history of multiple skin SCCs, which supports the
hypothesis of an increased susceptibility to develop this type
of cancer. Further investigations will be necessary to evaluate
the exact involvement of DSS1 in the development of skin
SCC and in other forms of cancer.
MATERIALS AND METHODS
SCC cases
FFPE tissue blocks of sporadic skin SCC (60) arising in unrelated
white Caucasian patients, paired with adjacent normal tissue, were
selected from the archives of the Dermatopathology Section,
Department of Human Pathology, University of Messina, Italy.
Patients ranged in age from 54 to 95 (mean age at diagnosis:
73.60±8 years) and included 39 men (65%) and 21 women (35%).
Of the 60 patients, 21 (35%) had a personal history of skin cancer
and 2 (3.3%) had a positive family history of skin SCC.
Controls
A total of 200 healthy controls (48.1% women, 51.9% men),
matched with the 60 patients with skin SCC with regard to age,
gender, and geographic origin (southern Italy), were recruited for
DSS1 genotype study. All controls had a negative history of skin
cancers. All subjects gave written informed consent. The investiga-
tion adhered to the Declaration of Helsinki Principles and was
approved by the ethics committee of the University of Messina.
Cell lines
DSS1 mutational analysis was performed on DNA extracted from
27 human cancer cell lines, including 3 from melanoma (MEL8863, G-
361, and GR-M), 11 from colon cancer (COLO205, Ht29, CaCo2,
WiDr, DLD1, CBS, Geo, LS-174T, SW480, SW620, and MIP-101), 11
from breast cancer (BT20, MDA-MB231, EVSA T, HCC1937, BT474,
MDA-MB134, MDA-MB157, MDA-MB361, MCF10A, T47D, and
SKBR3), 1 from ovarian cancer (OVCAR3), and 1 from T cell leukemia
(Jurkat). G-361 and GR-M were obtained from the European Collection
of Animal Cell Cultures (Sigma-Aldrich, St Louis, MO). All other cell
lines, except MEL8863, CBS, Geo, MIP-101, and EVSA T, were supplied
by the American Type Culture Collection (Manassas, VA). Cells were
grown under recommended culture conditions.
DNA extraction
FFPE sections were collected on microscope slides. Tumor and
tumor-free areas were identified and microdissected, using a
hematoxylin and eosin stained section from the same block as a
guide. DNA extraction from FFPE samples was performed by
QIAamp DNA Mini kit (Qiagen, Chatsworth, CA). Genomic DNA
was extracted from peripheral blood of control subjects and from
cell lines using the QIAamp blood kit (Qiagen).
Mutational analysis of the p53 gene
Exons 5–8 of the p53 gene (GenBank accession number X54156.1)
and the corresponding intron/exon borders were screened by PCR
and direct sequencing. PCRs were performed using a ‘‘semi-nested’’
amplification protocol with the primers listed in Supplementary
Table S1. PCRs were carried out in a 20 ml mixture containing
GeneAmp 10 PCR Buffer II (Applied Biosystems, Foster City, CA),
2.5 or 1.5mM MgCl2, 0.8mM of each deoxynucleotide triphosphate,
0.35mM of each primer, 6–10 ng of genomic DNA, and 5U ml1 of
AmpliTaq Gold DNA Polymerase (Applied Biosystems). PCR
conditions consisted of an initial step at 941C for 10minutes and
40 cycles of denaturation at 941C for 30 seconds, at primer annealing
temperature for 45 seconds and extension at 721C for 30 seconds,
followed by 1 cycle at 721C for 7minutes in a GenAmp PCR System
9700 (Applied Biosystems). PCR products were purified with Montage
PCR Units (Millipore, Bedford, MA), and both forward and reverse
strands were analyzed using an automated sequencer (Beckman
Coulter CEQ 2000 Analysis System; Beckman Coulter, Milan, Italy).
Mutational analysis of the DSS1 gene
PCR and direct sequencing of the DSS1 coding region (GenBank
accession number NG_009273.1) were performed using a ‘‘semi-
nested’’ amplification protocol with the primers reported in
Supplementary Table S1.
DSS1 genotyping
To analyze frequency in controls, we assessed the DSS1 c.143G4A
polymorphism by PCR-based restriction fragment-length polymorphism
assay, using a PCR forward primer containing a mismatch (GTA4GCA)
that introduced a TseI ‘‘GCAGC’’ control site. The 256bp PCR products
were digested with TseI (NEB, Hitchin, Hertfordshire, UK) at 651C
overnight, so that only the product carrying the G allele generated 120,
112, and 24bp fragments. The products of digestion were resolved on
4.5% agarose gels stained with ethidium bromide.
RNA extraction and QRT-PCR
Total RNA extraction from four unstained 20-mm FFPE sections
of each cutaneous SCC case and 21 adjacent normal skin samples
was performed with a RecoverAll Total Nucleic Acid Isolation kit
(Ambion, Austin, TX). Quantification of gene expression in normal
FFPE tissue was subject to limitations because, in some cases,
normal tissue was not sufficient. Synthesis of DSS1 complementary
DNA (cDNA) was performed using the ImProm-II Reverse Transcrip-
tion System (Promega, Madison, WI), using 1 mg of RNA in the
presence of random hexamers and RNAase inhibitor. QRT-PCR
was performed with TaqMan Universal PCR Master Mix (Applied
Biosystems), according to the manufacturer’s instructions. QRT-PCR
(Applied Biosystems) was performed as follows: 951C for 3minutes
and 40 cycles of PCR at 951C for 10 seconds, then 551C for 1minute.
All reactions were performed in triplicate. Primers were designed on
GenBank Reference Sequence NM_006304.1: forward, 50-GCGGA
CAGTCGAGATGTCAGA-30; and reverse, 50-CAAACTCGTCGTCTT
CCTCTAACA-30. The probe was 50-FAM-AGCCGGTAGACTTAGGT-
MGBNFQ-30. CT values were normalized to the endogenous reference
b-actin gene (Applied Biosystems).
mRNA secondary structure prediction
Prediction analysis was performed using the GeneBee Molecular
Biology Server (http://www.genebee.msu.su/genebee.html) bioinfor-
matics tool.
Immunohistochemistry
From each selected paraffin block, three 5-mm-thick tissue sections
were collected on xylane-coated slides and deparaffinized. Antigen
retrieval was performed by microwave treatment, and the endogen-
ous peroxidase was inactivated by 3% H2O2 in methanol. The
sections were incubated with polyclonal rabbit anti-DSS1 antibody
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(kindly provided by Kathrin Gudmundsdottir, Institute of Cancer
Research, London, UK), with peroxidase-labeled polymer conju-
gated to goat anti-rabbit immunoglobulins (DakoCytomation En-
Visionþ System-HRP; DakoCytomation, Carpinteria, CA) and with
3,30-diaminobenzidine and counterstained by Mayer’s hematoxylin.
Generation of DSS1 constructs
The constructs used for the transfection-based RNA stability assays
contained the whole DSS1 cDNA sequence (GenBank accession
number NM_006304.1). Total RNA was isolated using the RNAeasy
kit (Qiagen) from a skin biopsy of a heterozygous individual (obtained
with the patient’s informed consent) and reverse-transcribed using the
ImProm-II Reverse Transcription System (Promega). The encoding
region of DSS1 was then amplified using the primers DSS1-cDNAf
(50-ATGTCAGAGAAAAAGCAGCCGGTA-30) and DSS1-cDNAr (50-
TTATATCAAAACATTTATTTTTTGTGTTAC-30). The resulting DSS1
cDNA fragments containing either 143G allele or 143A allele, as
confirmed by DNA sequencing, were inserted into the pcDNA3.1
expression vector under the control of the CMV promoter/enhancer
(Invitrogen). Plasmid sequences and orientation were confirmed by
DNA sequencing and restriction enzyme analysis.
Cell culture and transfections
A total of 293 EBNA cells (ECACC no. 85120602) were grown in
DMEM (Sigma-Aldrich), supplemented with 10% fetal bovine serum
(Sigma-Aldrich), 50 IUml1 penicillin and streptomycin (EuroClone,
Milan, Italy), in 5% CO2 at 371C. Cells (5 105 per well) were
transfected with the DSS1 constructs using the DMRIE trans-
fection reagent (Invitrogen). At 48 hours after transfection, 5 mgml1
actinomycin D (Sigma-Aldrich) was added, and cells were grown
for another 24 hours before being harvested.
RNA stability assay
Total RNA was extracted from transfected cells, before and after
treatment with actinomycin D, using the TRIzol reagent (Invitrogen).
Reverse transcription was performed by ImProm-II Reverse Tran-
scription System (Promega) and random primers. We used
50-ATGTCAGAGAAAAAGCAGCCGGTA-30 (forward), 50-AGTCTTC
GGCAGGGAACTCTTCA-30 (reverse), and 50-FAM-GTCTGTTAG
AGGAAGACG-MGBNFQ-30 as primers and a TaqMan probe for
DSS1 (NCBI Reference Sequence: NM_006304.1); and 50-TGCTCC
TGCCGAGAAAGTATCCAT-30 (forward), 50-CTCGATGCGATGTTT
CGCTTGGT-30 (reverse), and FAM-50-TGCATACGCTTGATCCGG-
30-MGBNFQ as primers and a TaqMan probe for neomycin (NCBI
Reference Sequence: AY745746.1). Thermal cycling conditions
included activation at 951C (10minutes), followed by 40 cycles
each of denaturation at 951C (15 seconds), and annealing/elongation
at 601C (Applied Biosystems). The b-actin gene (Applied Biosystems)
was used as an internal control. Po0.05 was considered significant.
Statistical analysis
A nonparametric permutation analysis of variance by NPC test was
performed to establish the frequency of the DSS1 c.143G4A polymor-
phism among the subjects enrolled and to estimate DSS1 mRNA levels.
The P-value was estimated using the conditional Monte Carlo procedure.
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